Research Paper Volume 13, Issue 3 pp 3994—4006

Antiplatelet effect of ticagrelor with aspirin in acute minor stroke and transient ischemic attack stratified by CYP2C19 metabolizer status: subgroup analysis of the PRINCE trial

Inhibition of platelet aggregation (IPA) of Ticagrelor/aspirin therapy as compared with Clopidogrel/aspirin therapy during study time course stratified by metabolizer status.

Figure 3. Inhibition of platelet aggregation (IPA) of Ticagrelor/aspirin therapy as compared with Clopidogrel/aspirin therapy during study time course stratified by metabolizer status.